Loading stock data…
Ocular Therapeutix (OCUL)
$8.51-0.12 (-1.33%)
Market ClosedLast close Jul 24
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ocular Therapeutix, Inc. in the Healthcare sector is trading at $8.51 with a market capitalization of $1.9B. Wall Street consensus targets $27.09 (11 analysts), implying a +218.5% move over the next 12 months. The stock is currently 48% below its 52-week high of $16.44, remaining 16.5% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +218.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $10.79M↓ | $13.25M↓ | $14.54M↑ | $13.46M↑ | $10.70M |
| Gross Profit | $9.46M↓ | $11.66M↓ | $12.77M↑ | $11.52M↑ | $9.44M |
| Operating Income | -$93.34M↓ | -$69.76M↓ | -$68.70M↓ | -$67.64M↓ | -$63.92M |
| Net Income | -$88.61M↓ | -$64.65M↑ | -$69.42M↓ | -$67.81M↓ | -$64.05M |
Peer Comparison
JNJUNHPFE
Fundamentals
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.93B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-49.95%
Volume
Today's trading volume
1.13M
Recent News
Is Ocular Therapeutix (OCUL) Still Undervalued Or Is AXPAXLI Hope Already Priced In?
Ocular Therapeutix (OCUL) has drawn investor attention after recent trading saw the stock close at $8.62, with returns under pressure over the past month and past 3 months despite positive annual revenue growth. See our latest analysis for Ocular Therapeutix. Over a longer horizon, Ocular Therapeutix’s share price has come under pressure, with the year to date share price return down 27.07%, while the 3 year total shareholder return is up 100%. This points to strong historical swings in...
Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment
Ocular Therapeutix (NASDAQ:OCUL) said it remains on track to submit a New Drug Application for AXPAXLI in wet age-related macular degeneration in the fourth quarter, after what Executive Chairman, President and CEO Dr. Pravin Dugel described as alignment with the U.S. Food and Drug Administration on
3 Cash-Burning Stocks with Open Questions
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to significant downside.
3 Small-Cap Stocks with Open Questions
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Is Ocular Therapeuticx, Inc. (OCUL) Stock Positioned for Growth After Positive FDA Feedback on Axpaxli?
We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. Ocular Therapeuticx, Inc. (NASDAQ:OCUL) is among the best healthcare stocks. TheFly reported on June 18 that H.C. Wainwright increased its price target on OCUL to $25 from $21 while maintaining a Buy rating on the stock. The firm’s […]